Pneumonia remains one of the most common infectious disease diagnoses encountered by clinicians, yet significant questions persist about how best to diagnose and treat it. “Controversies in Pneumonia Diagnosis and Treatment,” at 3:15 p.m. ET, Thursday, Oct. 22, will examine several areas where evolving evidence and new technologies are challenging long-held practices.
Moderators Nongnooch Poowanawittayakom, MD, MPH, assistant professor of medicine at Rutgers New Jersey Medical School, and Chanu Rhee, MD, MPH, associate professor of medicine at Harvard Medical School, will lead a discussion featuring three experts addressing some of the field’s most debated topics.
Daniel A. Sweeney, MD, medical ICU director at Hillcrest Hospital and professor of medicine at the University of California-San Diego, will discuss corticosteroid use in severe community-acquired pneumonia. Prangthip Charoenpong, MD, MPH, assistant professor of medicine at Baylor College of Medicine, will explore navigating diagnostic uncertainty to optimize antibiotic use.
Romney Humphries, PhD, D(ABBM), executive medical director of laboratory medicine and pathology at Vanderbilt University Medical Center, will present “Molecular Diagnostic Panels for Pneumonia: Breakthrough or Overdiagnosis? Do Nonactionable Pathogen Results Matter?”
Challenging Assumptions
Taken collectively, the presentations will challenge assumptions and encourage attendees to reexamine standards that have often been accepted without question.
“Our goals are to press up against the standards of what we do,” Dr. Humphries said. “These are things that we’ve always done. Is it the right thing?”
Her presentation will focus on one of the most rapidly evolving areas of pneumonia management: molecular diagnostics. As laboratories increasingly adopt polymerase chain reaction tests and sequencing technologies capable of detecting a broad range of organisms, clinicians are grappling with how to interpret the results.
“What happens to a sample as it gets sent to the lab?” Dr. Humphries said. “Like a lot of things in medicine, as we adapt technologies and learn more, what is meaningful and what is not?”
One of the central questions is what clinicians should do when molecular tests detect bacteria that do not grow in traditional culture. Newer sequencing methods can identify even more organisms, raising additional questions about whether all detected microbes are clinically relevant.
Pneumonia diagnostics remain challenging because respiratory specimens often contain both pathogens and harmless colonizing organisms. Distinguishing between the two is not always straightforward, particularly when increasingly sensitive tests detect organisms that may not be causing disease.
Navigating Uncertainties
Dr. Charoenpong will address a different but closely related challenge in her presentation, “Pneumonia or Not? Navigating Diagnostic Uncertainty to Optimize Antibiotic Use.” She will examine how clinicians make treatment decisions when the diagnosis is unclear and how those decisions can affect patient outcomes.
As a transplant pulmonologist, Dr. Charoenpong said she faces this uncertainty “almost every day.” Pneumonia can resemble a number of noninfectious conditions, including acute rejection, organizing pneumonia, aspiration, pulmonary edema and pulmonary embolism, making diagnosis particularly challenging in complex patients.
Using two contrasting clinical cases, Dr. Charoenpong will explore the consequences of diagnostic errors in both directions. One case will involve an infection initially mistaken for a noninfectious condition, while the other will focus on a noninfectious pulmonary process treated as pneumonia, resulting in unnecessary antibiotic exposure.
“The question is not simply whether we should start antibiotics,” she said. “It’s how we continue gathering evidence, and we assess our initial diagnosis and decide whether we should narrow or even stop antibiotics.”
She also plans to discuss the limitations of imaging and microbiologic testing, the challenges of interpreting positive and negative results, and the importance of reassessing both diagnosis and treatment within 48 to 72 hours as new clinical information becomes available.
Ultimately, Dr. Humphries hopes attendees will leave the session with a better understanding of the strengths and limitations of emerging technologies and a clearer sense of where additional research is needed.